Summary: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors.
Description: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors. http://www.creativebiolabs.net/Anti-TnC-A1-Immunocytokine-scFv-F16-IL2-22493.htm
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
